Monoclonal Antibodies against Nalpha -(5'-Phosphopyridoxyl)-L-lysine
SCREENING AND SPECTRUM OF PYRIDOXAL 5'-PHOSPHATE-DEPENDENT ACTIVITIES TOWARD AMINO ACIDS*

(Received for publication, February 6, 1997)

Svetlana I. Gramatikova and Philipp Christen Dagger

From the Biochemisches Institut der Universität Zürich, CH-8057 Zürich, Switzerland

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Cofactors may be expected to expand the range of reactions amenable to antibody-assisted catalysis. The biological importance of pyridoxal 5'-phosphate (PLP) as enzymic cofactor in amino acid metabolism and its catalytic versatility make it an attractive candidate for the generation of cofactor-dependent abzymes. Here we report an efficient procedure to screen antibodies for PLP-dependent catalytic activity and detail the spectrum of catalytic activities found in monoclonal antibodies elicited against Nalpha -(5'-phosphopyridoxyl)-L-lysine. This hapten is a nonplanar analog of the planar, resonance-stabilized coenzyme-substrate adducts formed in the PLP-dependent reactions of amino acids. The hapten-binding antibodies were screened for binding of the planar Schiff base formed from PLP and D- or L-norleucine by competition enzyme-linked immunosorbent assay. The Schiff base (external aldimine) is an obligatory intermediate in all PLP-dependent reactions of amino acids. This simple, yet highly discriminating screening step eliminated most of the total 24 hapten-binding antibodies. Three positive clones bound the Schiff base with L-norleucine, two preferred that with the D-enantiomer. The positive clones were assayed for catalysis of Schiff base formation and of the alpha ,beta -elimination reaction with the D- and L-enantiomers of beta -chloroalanine. Three antibodies were found to accelerate aldimine formation, and two of these catalyzed the PLP-dependent alpha ,beta -elimination reaction. One of the alpha ,beta -elimination-positive antibodies catalyzed the transamination reaction with hydrophobic D-amino acids and oxoacids (Gramatikova, S. I., and Christen, P. (1996) J. Biol. Chem. 271, 30583-30586). All catalytically active antibodies displayed continuous turnover. No PLP-dependent reactions other than aldimine formation, alpha ,beta -elimination of beta -chloroalanine and transamination were detected. The successive screening steps plausibly simulate the functional selection pressures having been operative in the molecular evolution of primordial PLP-dependent protein catalysts to reaction- and substrate-specific enzymes.


INTRODUCTION

The first catalytic antibodies that became known accelerated relatively simple transformations; since then the antibody-catalyzed reactions have increased in complexity and degree of difficulty. Possible strategies to expand the catalytic scope of antibodies include the incorporation of cofactors such as metal ions, heme, thiamine, flavins, nicotinamide, or pyridoxal into the binding sites of the antibodies (1). Pyridoxal 5'-phosphate (PLP)1 is probably the most versatile enzymic cofactor. PLP is required by many enzymes that catalyze a wide variety of reactions in the metabolism of amino acids, i.e. transamination, racemization, decarboxylation, aldol cleavage, and elimination and replacement reactions (2). Several attempts to produce pyridoxal-dependent catalytic antibodies have been reported. In the earliest study, a polyclonal antiserum specific for the reduced Schiff base formed from PLP and 3'-amino-L-tyrosine was prepared. The antibodies slightly enhanced the rate of the PLP-catalyzed transamination of L-tyrosine (3-5). A monoclonal antibody against the reduced aldimine of pyridoxal and 4'-nitro-L-phenylalanine accelerated aldimine formation between 5'-deoxypyridoxal and 4'-nitro-D-phenylalanine but did not catalyze any further reactions (6). Catalysis of Schiff base formation was also observed with a polyclonal antiserum generated against the reduced Schiff base of pyridoxal and D- and L-phenylalanine (7).

The Schiff base 4 generated by condensation of PLP 1 and amino acid 2 (Fig. 1) is the first detectable intermediate common to all nonenzymic and enzymic PLP-dependent reactions of amino acids. In the enzymic reactions, the Schiff base is produced by transimination; the amino group of the substrate replaces the epsilon -amino group of the active-site lysine residue which covalently binds PLP in all B6 enzymes. The multiple possibilities for further reactions of the coenzyme-substrate aldimine 4 give rise to the diverse PLP-dependent transformations of amino acids (Scheme 1). Reduction of the imine double bond of the aldimine by sodium borohydride provides a stable link between the coenzyme and the amino acid. The Calpha -nitrogen linkage of the resulting phosphopyridoxyl amino acids 5 (Fig. 1) is similar to that in the tetrahedral carbinolamine transition state 3 leading to Schiff base formation (8). Phosphopyridoxyl amino acids bind with high affinity to apoenzymes (5, 9, 10) and include all groups important for catalysis with the exception of the imine double bond ensuring the planarity of the Schiff base (Fig. 1). Formation of the planar Schiff base is, however, a prerequisite for the catalytic efficacy of PLP which is due to the electron-withdrawing effect exerted on Calpha by the positively charged pyridine nitrogen atom and is mediated through the extensive resonance system of the pyridine ring and the imine double bond.


Fig. 1. Nonenzymic formation of the planar Schiff base 4 from PLP 1 and an amino acid 2. The nonplanar haptens 5 used in binding studies were Nalpha -(5'-phosphopyridoxyl)-Nepsilon -acetyl-L-lysine, Nalpha -(5'-phosphopyridoxyl)-L-lysine, Nalpha -(5'-phosphopyridoxyl)-3'-amino-L-tyrosine, Nalpha -(5'-phosphopyridoxyl)-D-tyrosine, Nalpha -(5'-phosphopyridoxyl)-L-alanine, and Nalpha -(5'-phosphopyridoxyl)-D-alanine. Nalpha -(5'-Phosphopyridoxyl)-L-lysine was coupled to maleylated keyhole limpet hemocyanin or BSA and used as antigen 6 for immunization and for ELISA, respectively.
[View Larger Version of this Image (14K GIF file)]



Scheme 1. Procedure for the selection of PLP-dependent catalytic antibodies. Shaded areas denote the catalytic events to which the screening steps indicated at the top were applied.
[View Larger Version of this Image (49K GIF file)]


In a renewed attempt to obtain PLP-dependent antibody catalysts, we used, as in the previous studies by other laboratories (3-7), a reduced Schiff base as hapten for immunization. The structural disadvantage of this transition state analog was, however, compensated by a special screening protocol. The selection of potential abzymes was based on immunodetection of binders of the Schiff base 4 rather than of the immunizing hapten 5. Binders of the aldimine were further screened for alpha , beta -elimination of beta -chloroalanine. This easily detectable reaction depends on the deprotonation at Calpha which is an integral step in the by far largest group of PLP-dependent reactions of amino acids (Scheme 1).


EXPERIMENTAL PROCEDURES

Preparation of Haptens, Antigens, Antibody Production and Purification

The synthesis of the haptens 5 and the protein conjugates 6 (Fig. 1) was described previously (3, 11). The hapten Nalpha -(5'-phosphopyridoxyl)-L-lysine was coupled to maleylated carrier protein (12) which was keyhole limpet hemocyanin or bovine serum albumin (BSA) for immunization and ELISA, respectively. Monoclonal antibodies were generated as described previously (11). The antibodies were purified by affinity chromatography on protein G-Sepharose 4 Fast Flow from Pharmacia Biotech Inc. The concentration of antibody was measured photometrically (E280,mg/ml = 1.4).

Screening for Hapten Binding

The hybridoma supernatants were screened by ELISA 10-14 days after the fusion. Maxisorp plates from Nunc were coated with hapten-BSA conjugate 6 (10 µg/ml in 50 mM sodium carbonate, pH 9.6, 50 µl/well) for 1 h at 37 °C, washed with washing buffer (phosphate-buffered saline, 0.05% Tween 20, 0.02% sodium azide), and blocked with BSA (1% w/v in washing buffer, 300 µl/well) for 30 min at 37 °C. The hybridoma supernatants (50 µl/well) were added and the plates incubated for 1 h at 37 °C. The binding of the antigen was detected, after a washing step, with an alkaline phosphatase-labeled second antibody from Sigma. Binders of Nalpha -(5'-phosphopyridoxyl)-L-lysine were selected by comparison of the binding of hapten-BSA conjugate, maleylated BSA, and unmodified BSA.

Competition ELISA

The inhibitory effects of PLP (0.1-2 mM, depending on the antibody), PLP plus 25 mM D- or L-norleucine, and PLP plus 25 mM glycine on antibody-antigen binding were estimated. Diluted hybridoma supernatant or purified antibodies were preincubated with the inhibitors in bis-tris propane/NaCl (50 mM bis-tris propane, 140 mM NaCl), pH 7.5, at 37 °C for 30 min in the dark. The incubation mixtures were added into the wells that had been coated with antigen (see above), and the plate was incubated for 30 min at 37 °C in the dark. The amount of the bound antibody was measured after addition of an alkaline phosphatase-labeled second antibody from Sigma (for details, see Ref. 11).

Measurement of the Rate of Schiff Base Formation

The purified antibodies and the D- or L-enantiomer of Nepsilon -acetyllysine were mixed in bis-tris propane/NaCl, pH 7.5, at 25 °C. The reaction was started by the addition of PLP. The final concentrations of the antibody, PLP, and the amino acid were 2.5 µM, 16 µM and 1 mM, respectively. The absorbance of the reaction mixture was monitored in the range of 410-450 nm, depending on the antibody, with an HP 8453 spectrophotometer. This wavelength range corresponds to the absorption band of the protonated Schiff base (2, 5).

Determination of alpha ,beta -Elimination Activity

The production of pyruvate in the presence of 10 µM antibody, 100 µM PLP, and 10 mM D- or L-enantiomers of beta -chloroalanine in bis-tris propane/NaCl, pH 7.0, at 25 °C in the dark was measured with lactate dehydrogenase and NADH. A control reaction without antibody was run under the same conditions. Absorbance at 340 nm was measured with an HP 8453 spectrophotometer. The calculation of all catalytic activities is based on the concentration of binding sites of the antibodies.

Measurements of Tritium Release

The reaction mixtures (40 µl) contained 25 µM antibody, 1 mM PLP, 25 mM glycine, and 106 cpm of [2-3H]glycine (Isotopchim) with a specific radioactivity of 30 Ci/mmol in bis-tris propane/NaCl, pH 7.0. After an incubation of 1 h at 25 °C in the dark, the released tritium was measured in 10-µl samples as described previously (5).

Determination of Transaminase Activity

The reaction mixtures contained 5-10 µM antibody, 200 µM PLP, and 200 mM D/L-alanine in bis-tris propane/NaCl, pH 7.5, at 25 °C in the dark. The increase in both absorbance at 325 nm (epsilon = 8,300 M-1 cm-1; Ref. 13) and fluorescence (excitation wavelength 325 nm, wavelength of maximum emission 389 nm) was used to detect PMP as product of transamination. The negative control without antibody was measured under the same conditions. In the case of very low activity, detection of catalysis by fluorescence is the method of choice because of its higher sensitivity.

HPLC Analysis for Detection of PLP-dependent Transformations of Amino Acids

The reaction mixtures contained 25 µM antibody, 0.1-1 mM PLP (depending on the binding affinity of the individual antibodies for the cofactor as estimated by competition ELISA), and 100 mM amino acid in bis-tris propane/NaCl, pH 7.5, at 25 °C in the dark. Samples were taken during a period of 6 h, derivatized with Marfey reagent, and analyzed by reverse phase HPLC (14). Newly generated peaks were identified by comparison with reference substances.

Measurements of Dissociation Equilibrium Constants

The Kd' values of antibody 15A9 for the haptens 5 (Fig. 1), PLP, and PMP were determined by measuring the quenching of the intrinsic fluorescence of the antibody (excitation wavelength 280 nm; wavelength of maximum emission 342 nm). The concentration of the abzyme was in the range of 0.01-0.8 µM. The measurements were performed at 25 °C in bis-tris propane/NaCl, pH 7.5, with a Spex Fluorolog spectrofluorometer and were corrected for the fluorescence of the ligand itself. Kd' values were calculated by nonlinear regression analysis.


RESULTS

Screening for Aldimine Binding

Because the imine double bond of Schiff base 4, which is essential for PLP to exert its catalytic effect, was absent in the hapten Nalpha -(5'-phosphopyridoxyl)-L-lysine 5 (Fig. 1), we introduced an additional screening step to select from the 24 hapten-binding antibodies those that bind also the planar aldimine 4. PLP readily forms Schiff bases with primary amino groups in an uncatalyzed equilibrium reaction. Thus, a competition ELISA of the antibody-antigen binding with PLP and amino acids as inhibitors was used to identify the binders of the Schiff base (Scheme 1). Binders of the aldimine were expected to be inhibited more strongly by PLP plus amino acid than by PLP or the amino acid alone. As amino acid ligands for these competitive binding assays we chose D- and L-norleucine and glycine. Antibodies 13B10, 8H4, 15A9, 11C2, and 14G1 showed indeed that their binding to the antigen was inhibited more strongly in the presence of PLP plus 25 mM glycine and PLP plus 25 mM D- or L-norleucine than in the presence of PLP or the amino acid alone (Fig. 2). The inhibition of antibody-antigen binding by the Schiff base 4 formed from PLP plus glycine indicates the existence of a binding site for the amino acid moiety of the hapten, and the difference in inhibition by PLP plus norleucine and PLP plus glycine reflects the contribution of the amino acid side chain to the binding of the Schiff base. In antibodies 13B10, 15A9, and 11C2 the side chain of L-norleucine positively contributed to the binding of the Schiff base. In antibody 14G1, a small positive contribution by the side chain of D-norleucine was observed. In all cases, except for antibody 11C2, the contribution of the side chain of the enantiomeric amino acid was negative. Antibody 8H4 bound the Schiff base with both D- and L-norleucine less tightly than that with glycine. The inhibition profiles of antibodies 5G12 and 6E9 are displayed in Fig. 2 to illustrate the binding properties of the great majority of the antibodies which did not show a significant difference in the inhibition by PLP and by PLP plus amino acids. Apparently, these antibodies cannot accommodate the planar aldimine adduct in their binding site. The inhibition tests were applied to supernatants as well as purified antibodies. The observed differences were negligible.


Fig. 2. Competition ELISA of antibodies for aldimine binding. The Schiff base 4 was formed from PLP in the presence of D- or L-norleucine and glycine. The assay measures the binding of the antibodies to the antigen 6 in the absence and presence of PLP 1 or PLP and amino acid 2, which react nonenzymically to form the Schiff base 4. Cofactor concentration was chosen on the basis of the antibody affinity as estimated by competition ELISA. For antibodies 13B10, 15A9, 11C2, 6E9, and 5G12, PLP concentration was 100 µM; for 8H4 and 14G1, it was 1 and 2 mM, respectively. The amino acid concentration was 25 mM. These conditions ensured that at least 80% of the cofactor in the incubation mixture was present as Schiff base. In all cases, inhibition of antibody-antigen binding by the amino acids alone was negligible.
[View Larger Version of this Image (51K GIF file)]


The immunological test for aldimine binding was validated by the detection of catalysis of aldimine formation by part of the selected antibodies. Purified antibodies 13B10 and 15A9 catalyzed Schiff base formation between PLP and Nepsilon -acetyl-L-lysine, and antibody 8H4 between PLP and Nepsilon -acetyl-D-lysine. The stereospecificity of directly measured aldimine formation thus correlates with the stereospecificity of aldimine binding as assessed by competition ELISA. The best catalyst, antibody 15A9, showed a marked acceleration of the condensation reaction at a PLP concentration of 16 µM, which is considerably below its K'd value of 90 µM (Fig. 3). Under the same conditions, antibodies 8H4 and 13B10 also showed significant rate acceleration. Determination of the initial rate at higher concentrations of PLP and amino acid was not possible because the formation of Schiff base would become too fast to be followed without rapid-kinetics methodology. Antibodies 11C2, 14G1, 5G12, and 6E9 did not catalyze aldimine formation.


Fig. 3. Acceleration of Schiff base formation by antibody 15A9. The reaction was started by the addition of 16 µM PLP to 1 mM Nepsilon -acetyl-L-lysine and 2.5 µM antibody in bis-tris propane/NaCl, pH 7.5, at 25 °C (bullet ); control reaction without antibody (open circle ). At equilibrium, the difference in aldimine formed between the control and the reaction in the presence of antibody apparently corresponds to antibody-bound aldimine, which amounts to about 80% of the concentration of antibody binding sites. No detectable catalysis of aldimine formation by 15A9 was observed even at higher concentrations of PLP and the D-enantiomer of the amino acid.
[View Larger Version of this Image (13K GIF file)]


Screening for Deprotonation at Calpha

Deprotonation at Calpha of the substrate is an integral step in the reaction pathways of the by far largest group of PLP-dependent reactions of amino acids (Scheme 1). The substrate analog beta -chloroalanine has been reported to act as a mechanism-based inhibitor of several B6 enzymes (15). Because of the good leaving group in the beta -position, deprotonation at Calpha is spontaneously followed by alpha ,beta -elimination. The resulting aminoacrylate intermediate may react with protein side chains or decompose to chloride, ammonia, and easily detectable pyruvate (Fig. 4). Pyruvate production may thus serve as an indicator of Calpha -deprotonation. The potential catalysts, i.e. the aldimine-binding antibodies 13B10, 8H4, 15A9, 11C2, and 14G1, were screened for PLP-dependent activity toward the D- and L-enantiomers of beta -chloroalanine (see "Experimental Procedures"). Antibody 15A9 showed alpha ,beta -elimination activity toward beta -chloro-D-alanine (kcat' = 50 min-1), and antibody 13B10 proved active toward beta -chloro-L-alanine kcat' = 5 min-1). Antibodies 8H4, 11C2, 14G1, 5G12, and 6E9 did not show any detectable activity toward either enantiomer. The Nepsilon -acetyl-L-lysine containing hapten 9 (20 µM) completely inhibited the alpha ,beta -elimination reaction of beta -chloro-L-alanine catalyzed by antibody 15A9, indicating that the catalytic effect of the antibody is due to its specific binding sites.


Fig. 4. alpha ,beta -Elimination reaction of beta -chloroalanine (15).
[View Larger Version of this Image (14K GIF file)]


Measurement of tritium release from [2-3H]glycine was used to confirm the PLP-dependent antibody 15A9-catalyzed deprotonation at Calpha (for details, see "Experimental Procedures"). Three control experiments containing PLP plus glycine without protein, PLP plus glycine and unspecific IgG, and antibody 15A9 plus glycine without PLP, were performed. The amount of released tritium in the test sample was corrected for that in the control with PLP plus glycine and corresponded to an estimated value of kcat' congruent  7 min-1, considering an isotope effect of 10 and the half-saturation of the antibody with the substrate glycine.

Detection of PLP-dependent Amino Acid Transformations

The specific absorption and fluorescence properties make PMP an easily detectable product of the transamination reaction. Antibodies 13B10, 8H4, 14G1, and 11C2 did not accelerate the transamination reaction of PLP and D/L-alanine. Antibody 15A9 was found to catalyze the transamination reaction of PLP with D-alanine (Fig. 5) and other hydrophobic D-amino acids (11). The kcat' value for transamination with D-alanine was 0.42 min-1, corresponding to a 5,000-fold rate acceleration compared with the catalytic effect of PLP alone (11). Antibody 15A9 has been shown previously by HPLC analysis not to catalyze any reaction of amino acids other than transamination. The same analysis was applied to antibody 13B10 (see "Experimental Procedures"). No racemization, decarboxylation, or elimination reaction with D/L-alanine and D/L-serine was observed.


Fig. 5. Antibody 15A9-catalyzed transamination reaction. The absorbance measurements were performed in bis-tris propane/NaCl, pH 7.5, at 25 °C. The concentration of the antibody was 5 µM. The concentration of the cofactor and the substrate D-alanine was 200 µM and 200 mM, respectively. The consumption of the protonated Schiff base was followed at 410 nm and the production of PMP at 325 nm.
[View Larger Version of this Image (17K GIF file)]


Binding Affinity for Phosphopyridoxyl Amino Acids

The dissociation equilibrium constants of antibody 15A9 for different phosphopyridoxyl amino acids 5, PLP, and PMP were determined by measuring the quenching of the intrinsic tryptophan fluorescence of the antibodies upon addition of ligand (Fig. 6). A comparison of the dissociation constants indicates the presence of binding sites for both the cofactor and the amino acid moiety (Table I). The antibody exhibits a relatively broad tolerance for the amino acid portion of the hapten. L-Amino acids as well as D-amino acids can be bound. Remarkably, 3'-amino-L-tyrosine is a very good ligand. The lowest dissociation constant was measured with the hapten Nalpha -(5'-phosphopyridoxyl)-Nepsilon -acetyl-L-lysine, which structurally resembles to a maximum extent antigen 6.


Fig. 6. Fluorescence titration of antibody 15A9 with PLP. The measurements were performed in bis-tris propane/NaCl, pH 7.5, at 25 °C. The concentrations of the cofactor were 20, 40, 53, 70, 90, 106, 140, and 170 µM. For details, see "Experimental Procedures."
[View Larger Version of this Image (26K GIF file)]


Table I.

Dissociation equilibrium constants of antibody 15A9 for phosphopyridoxyl amino acids and cofactors

The constants were determined by measurement of quenching of the intrinsic antibody fluorescence at pH 7.5 (see "Experimental Procedures").


Ligand K'd

µM
Nalpha -(5'-Phosphopyridoxyl)-Nepsilon -acetyl-L-lysinea 0.026
Nalpha -(5'-Phosphopyridoxyl)-L-lysine 2
Nalpha -(5'-Phosphopyridoxyl)-3'-amino-L-tyrosine 0.06
Nalpha -(5'-Phosphopyridoxyl)-D-tyrosine 1.7
Nalpha -(5'-Phosphopyridoxyl)-L-alaninea 1.4
Nalpha -(5'-Phosphopyridoxyl)-D-alaninea 1.5
PLPa 90
PMPa 40

a From Ref. 11. The value of K'm for PLP in both the transamination reaction with D-alanine and the alpha ,beta -elimination reaction with beta -chloro-L-alanine was ~90 µM; the value of Kd for PLP in the competition ELISA (see Fig. 2) was 120 µM.


DISCUSSION

The multitude of possible transformations products of amino acids (Scheme 1) is a major problem in the design of a screening procedure for PLP-dependent catalytic antibodies. In view of this difficulty, we have devised a protocol that screens for the occurrence of two successive crucial reaction steps rather than for a final product. The first step for which the antibodies were screened was the binding of the PLP-amino acid aldimine 4 (Fig. 1). This selection, easily executed with a competition ELISA (Fig. 2), was particularly important because we used, as in previous studies by other laboratories (5-7), the reduced and thus nonplanar Schiff base 5 as hapten for the immunization. However, formation of the extended planar resonance system, encompassing the pyridine ring of the coenzyme and the imine double bond, is essential for the cleavage of one of the bonds between Calpha and its substituents (2). In the next screening step, the antibodies were selected for catalysis of the breaking of the Calpha -H bond, which in most PLP-dependent reactions of amino acids follows the formation of the aldimine (Scheme 1). The substrate analog beta -chloro-D/L-alanine provided a simple and generally applicable assay for deprotonation at Calpha (Fig. 4). Only antibodies that catalyzed both aldimine binding and alpha -deprotonation were analyzed with HPLC for the generation of specific reaction products from both enantiomers of different amino acids.

The screening procedure clearly defines the requirements that have to be met by an enzyme mimic to catalyze a PLP-dependent transformation of an amino acid (Scheme 1). As a corollary, the successive selection steps plausibly simulate the functional selection pressures that presumably were operative in the molecular evolution of B6 enzymes. Comparison of amino acid sequences has shown that the B6 enzymes are of multiple evolutionary origin (16-18). As required for a PLP-dependent catalytic antibody, the ancestor protein of a B6 enzyme family very likely had to possess a PLP and an amino acid binding site with a geometry that accommodated the planar aldimine. Competition ELISA (Fig. 2), as well as the Kd' values for haptens determined with antibody 15A9 (Table I), indicated that both the coenzyme and substrate moiety interact with the catalytically active antibodies. Recognition of the amino acid side chain is evident from the enantiomeric specificity of the antibodies in the competition ELISA (Fig. 2), which varies in kind and degree, as well as from the order of preference of amino acids in aldimine binding, which invariably was N-acetyl-lysine > norleucine > alanine > glycine.2 Although the immunizing hapten was a derivative of an L-amino acid, two of the five aldimine-binding antibodies preferred D-amino acids (Fig. 2). The type of binding of PLP to the antibodies has been examined only in 15A9, the only antibody that catalyzes a transformation of an amino acid other than beta -chloroalanine. Antibody 15A9 appears to bind PLP noncovalently (11). Both experiments with nonenzymic model systems3 (19) and the residual activity of mutant PLP-dependent enzymes without active-site lysine residue (20, 21) have indicated that formation of the coenzyme-substrate aldimine by transimination rather than de novo formation from PLP and amino acid is not essential for catalysis. The ubiquitous occurrence of the coenzyme-binding lysine residue might reflect a historic trait rather than a mechanistic necessity (16, 22). Covalent binding of PLP probably was the very first step in the molecular evolution of B6 enzymes. Primordial B6 enzymes presumably had to cope with low concentrations of the cofactor. In contrast, at the high concentrations of PLP and amino acid used in our experiments aldimine is preformed from unbound PLP and amino acid at a rate fast enough and present in a concentration high enough to serve directly as substrate for the abzymes.

The selection of aldimine-binding antibodies was followed by screening for a catalytic effect, i.e. the cleavage of the Calpha -H bond of the substrate moiety. In the molecular evolution of B6 enzymes, the analogous step after acquiring the capacity of aldimine binding may be assumed to have been the development of a catalytic apparatus facilitating the cleavage of one of the bonds between Calpha and its substituents. The easily measured alpha ,beta -elimination of beta -chloro-D/L-alanine (Fig. 4) served to test for Calpha -deprotonation, which underlies the majority of PLP-dependent reactions of amino acids (Scheme 1). Antibody 13B10 was found to catalyze the alpha ,beta -elimination of beta -chloro-L-alanine which is consistent with its enantiomeric binding specificity. In contrast, antibody 15A9, which preferably binds the aldimine with L-amino acids (Fig. 2), catalyzed both the alpha ,beta -elimination and the transamination reaction exclusively with D-amino acids. Apparently, the Calpha -H bond of the L-amino acid substrate is directed toward an inert surface region of the antibody (11).

Three reactions were found to be catalyzed by the antibodies: formation of aldimine, deprotonation at Calpha as reflected by alpha ,beta -elimination of beta -chloroalanine, and transamination. Catalysis of aldimine formation might reflect a favorable relative orientation of bound PLP and amino acid. alpha ,beta -Elimination of beta -chloroalanine and transamination share one important feature: the crucial reaction steps are proton transfers (Scheme 1). Apparently, in antibody 13B10 and 15A9 acid-base groups are positioned in proximity of Calpha and Calpha /C4', respectively. Alternatively, water molecules might have access to these atoms and mediate the proton transfers. With antibody 15A9, transamination is 2 orders of magnitude slower than alpha ,beta -elimination, suggesting that reprotonation at C4' is rate-limiting.

Antibody 15A9 is the only antibody catalyzing the transformation of a natural amino acid. The antibody is remarkably reaction-specific, transamination being the only reaction that is observed. The antibody accelerates the transamination reaction not only of PLP and an amino acid but also in the reverse direction with PMP and an oxoacid as substrates (11). The orientation of the Calpha -substituents relative to the plane of the resonance system of imine and coenzyme together with the presence (and absence) of catalytically effective protein side chains serving as general acid-base groups or modulating the electron repartition in the coenzyme-substrate adduct are thought to determine the reaction specificity in B6 enzymes (23, 24). In contrast to the reaction specificity, the substrate specificity of 15A9 is less strictly defined, apparently all hydrophobic amino acids, and oxoacids in the reverse reaction with PMP, are generally accepted as substrates (11). Thus, the results of the successive steps in the functional screening of PLP-dependent antibody catalysts correspond to the molecular evolution of B6 enzymes also with respect to the development of specificity. In the evolution of B6 enzymes, specialization for reaction specificity clearly preceded that for substrate specificity (16, 25). The analogy reflects the interplay of chance and necessity being operative in both cases.


FOOTNOTES

*   This work was supported in part by Swiss National Science Foundation Grant 31.36542.92 and by the Cost Action-D7 Program of the European Cooperation in the Field of Scientific and Technical Research.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Biochemisches Institut der Universität Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland. Tel.: 41-1-257-5560; Fax: 41-1-363-7947; E-mail: christen{at}biocfebs.unizh.ch.
1   The abbreviations used are: PLP, pyridoxal 5'-phosphate; B6 enzymes, PLP (vitamin B6)-dependent enzymes; BSA, bovine serum albumin; bis-tris, 2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-propane-1,3-diol; ELISA, enzyme-linked immunosorbent assay; PMP, pyridoxamine 5'-phosphate; HPLC, high performance liquid chromatography.
2   H. Staub, S. I. Gramatikova, and P. Christen, unpublished data.
3   H. P. Tobler, H. Gehring, and P. Christen, unpublished data.

ACKNOWLEDGEMENTS

We thank Beat Kunz, Hans Wendt, and Stefan Bienz for assistance in practical aspects of the work. We are grateful to Heinz Gehring and Hans Hengartner for helpful discussions.


REFERENCES

  1. Lerner, R. A., Benkovic, S. J., and Schultz, P. G. (1991) Science 252, 659-667 [Medline] [Order article via Infotrieve]
  2. Jencks, W. P. (1969) Catalysis in Chemistry and Enzymology, pp. 133-146, McGraw Hill, New York
  3. Raso, V., and Stollar, B. D. (1973) J. Am. Chem. Soc. 95, 1621-1628 [Medline] [Order article via Infotrieve]
  4. Raso, V., and Stollar, B. D. (1975) Biochemistry 14, 584-591 [Medline] [Order article via Infotrieve]
  5. Raso, V., and Stollar, B. D. (1975) Biochemistry 14, 591-599 [Medline] [Order article via Infotrieve]
  6. Cochran, A. G., Pham, T., Sugasawara, R., and Schultz, P. G. (1991) J. Am. Chem. Soc. 113, 6670-6672
  7. Tubul, A., Brun, P., Michel, R., Gharib, B., and De Reggi, M. (1994) Tetrahedron Lett. 35, 5865-5868 [CrossRef]
  8. Auld, D. S., and Bruice, T. C. (1967) J. Am. Chem. Soc. 89, 2083-2097
  9. Heller, J. S., Canellakis, E. S., Bussolotti, D. L., and Coward, J. K. (1975) Biochim. Biophys. Acta 403, 197-207 [Medline] [Order article via Infotrieve]
  10. Khomutov, R. M., Dixon, H. B. F., Vdovina, L. V., Kirpichnikov, M. P., Morozov, Y. V., Severin, E. S., and Khurs, E. N. (1971) Biochem. J. 124, 99-106 [Medline] [Order article via Infotrieve]
  11. Gramatikova, S. I., and Christen, P. (1996) J. Biol. Chem. 271, 30583-30586 [Abstract/Free Full Text]
  12. Freedman, M. H., Grossberg, A. L., and Pressman, D. (1968) Biochemistry 7, 1941-1950 [Medline] [Order article via Infotrieve]
  13. Peterson, E. A., and Sober, H. A. (1954) J. Am. Chem. Soc. 76, 169-175
  14. Kochhar, S., and Christen, P. (1989) Anal. Biochem. 178, 17-21 [Medline] [Order article via Infotrieve]
  15. Morino, Y., Osman, A. M., and Okamoto, M. (1974) J. Biol. Chem. 249, 6684-6692 [Abstract/Free Full Text]
  16. Alexander, F., Sandmeier, E., Mehta, P. K., and Christen, P. (1994) Eur. J. Biochem. 219, 953-960 [Abstract]
  17. Christen, P., Mehta, P. K., and Sandmeier, E. (1994) in Biochemistry of Vitamin B6 and PQQ (Marino, G., Sannia, G., and Bossa, F., eds), pp. 9-13, Birkhäuser, Basel, Switzerland
  18. ürichHuber, B. (1996) Diploma thesis, University of Zürich
  19. Schonbeck, N. D., Skalski, M., and Shafer, J. A. (1975) J. Biol. Chem. 250, 5343-5351 [Abstract]
  20. Ziak, M., Jäger, J., Malashkevich, V. N., Gehring, H., Jaussi, R., Jansonius, J. N., and Christen, P. (1993) Eur. J. Biochem. 211, 475-484 [Abstract]
  21. Futaki, S., Ueno, H., Martinez del Pozo, A., Pospischil, M. A., Manning, J. M., Ringe, D., Stoddard, B., Tanizawa, K., Yoshimura, T., and Soda, K. (1990) J. Biol. Chem. 265, 22306-22312 [Abstract/Free Full Text]
  22. Christen, P., Kasper, P., Gehring, H., and Sterk, M. (1996) FEBS Lett. 389, 12-14 [CrossRef][Medline] [Order article via Infotrieve]
  23. Dunathan, H. C. (1966) Proc. Natl. Acad. Sci. U. S. A. 55, 712-716 [Medline] [Order article via Infotrieve]
  24. Graber, R., Kasper, P., Malashkevich, V. N., Sandmeier, E., Berger, P., Gehring, H., Jansonius, J. N., and Christen, P. (1995) Eur. J. Biochem. 232, 686-690 [Abstract]
  25. Sandmeier, E., Hale, T., and Christen, P. (1994) Eur. J. Biochem. 221, 997-1002 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.




This Article
Abstract
Full Text (PDF)
Purchase Article
View Shopping Cart
Alert me when this article is cited
Alert me if a correction is posted
Citation Map
Services
Email this article to a friend
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Copyright Permissions
Google Scholar
Articles by Gramatikova, S. I.
Articles by Christen, P.
Articles citing this Article
PubMed
PubMed Citation
Articles by Gramatikova, S. I.
Articles by Christen, P.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   Biochemistry and Molecular Biology Education 
Copyright © 1997 by the American Society for Biochemistry and Molecular Biology.